Records containing: Schizophrenia
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-12-09Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
-
CLINICAL_TRIALS study record update · 2025-12-08Pharmacologic Treatment in Legal Offenders With Schizophrenia, a Prospective Observational Mirror Image Study
-
CLINICAL_TRIALS study record update · 2025-12-05Risperidone ISM® Effectiveness in Schizophrenia Patients Hospitalised Due to A Relapse: a Prospective Non-interventional Evaluation (RESHAPE Study)
-
CLINICAL_TRIALS study record update · 2025-12-05An Open Label, Randomized, Two-period, Twotreatment, Two-sequence, Truncated, Crossover, Balanced, Single Dose Oral Bioequivalence Study.
-
CLINICAL_TRIALS study record update · 2025-12-05Effectiveness of Navigated Transcranial Magnetic Stimulation (nTMS) of Left Supramarginal Gyrus for Negative Symptoms : A Double-blind, Randomized Controlled Trial
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-12-05A Multicenter, Randomized, Open-Label, Parallel-Group, Multiple-Dose Bioequivalence Study of Paliperidone Palmitate Injection in Chinese Patients With Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-12-04Imagery Rescripting for Early Psychosis: a Multiple-Baseline Single-Case Experimental Design.
-
CLINICAL_TRIALS study record update · 2025-12-02Feasibility and Acceptability of Mobile Mental Health Application for the Improvement of Medication Adherence in Persons With Schizophrenia(SZ) and Schizoaffective Disorder(SZA)
-
CLINICAL_TRIALS study record update · 2025-12-02A Pilot Study to Assess the Effect of Prucalopride on Cognitive Functioning in Patients With Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-11-25A Randomized Controlled Trial to Evaluate Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-11-24Implementing mHealth for Schizophrenia in Community Mental Health Settings
-
CLINICAL_TRIALS study record update · 2025-11-21A Phase 3, Multicenter, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-11-21Effect of Immersive Virtual Reality-based Cognitive Remediation in Patients With Mood Disorders or Psychosis Spectrum Disorders: a Randomized, Controlled, Double-blinded Trial
-
CLINICAL_TRIALS study record update · 2025-11-19A Randomized, Double-Blind, Placebo-Controlled, Dose- Ascending Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of LPM787000048 Maleate Extended-Release Tablets (LY03020) in Chinese Adult Healthy Subjects and/or Subjects With Stable Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-11-18Prospective 12-week Randomized Controlled Trial (RCT) of Remotely- Delivered Customized Adherence Enhancement for Poorly Adherent Individuals With Schizophrenia (CAE-S) vs Enhanced Treatment as Usual (eTAU)
-
CLINICAL_TRIALS study record update · 2025-11-18Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness
-
CLINICAL_TRIALS study record update · 2025-11-12An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia Switched From Typical or Atypical Antipsychotic Agents
-
CLINICAL_TRIALS study record update · 2025-11-12An 8-Week, Open-Label Study Evaluating the Effectiveness, Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia Switched From Typical or Atypical Antipsychotic Agents
-
CLINICAL_TRIALS study record update · 2025-11-12An Open-label Multiple Oral Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lumateperone in Patients, Ages 13 to 17 Years, Diagnosed With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2025-11-12Single-Blind Randomized Ketogenic Diet vs. Control Diet in People With Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-11-05Motivation Skills Training to Enhance Functional Outcomes for People With Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-11-05A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-1)
-
CLINICAL_TRIALS study record update · 2025-11-05Optimizing Cognitive Behavioral Social Skills Training With Executive Function Training for Older Adults With Schizophrenia
-
CLINICAL_TRIALS study record update · 2025-10-28A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
-
CLINICAL_TRIALS study record update · 2025-10-27A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder